Notably, Pembrolizumab is recommended for monotherapy as first-line treatment for NSCLC patients without oncogenic driving mutations and with a high PD-L1 expression (tumor proportion score (TPS) ≥ 50%). Here, CD274 is linked to non-small cell lung carcinoma.